PE20061109A1 - Nueva sal y polimorfos del inhibidor de la dpp-iv - Google Patents

Nueva sal y polimorfos del inhibidor de la dpp-iv

Info

Publication number
PE20061109A1
PE20061109A1 PE2006000304A PE2006000304A PE20061109A1 PE 20061109 A1 PE20061109 A1 PE 20061109A1 PE 2006000304 A PE2006000304 A PE 2006000304A PE 2006000304 A PE2006000304 A PE 2006000304A PE 20061109 A1 PE20061109 A1 PE 20061109A1
Authority
PE
Peru
Prior art keywords
dpp
polymorphes
inhibitor
refers
characteristic peaks
Prior art date
Application number
PE2006000304A
Other languages
English (en)
Inventor
Stefan Abrecht
Andre Gerard Bubendorf
Stephan Goetzoe
Francois Montavon
Franziska Rohrer
Michelangelo Scalone
Shaoning Wang
Urs Schwitter
Armin Ruf
Regina Moog
Olaf Grassmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20061109A1 publication Critical patent/PE20061109A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN POLIMORFO DE MESILATO DE (S)-1-{[2-(5-METIL-2-FENIL-OXAZOL-4IL)-ETILAMINO]-ACETIL}-PIRROLIDINA-2-CARBONITRILO CARACTERIZADO POR UN MODELO DE DIFRACCION DE RAYOS X DE MATERIAL EN POLVO QUE TIENE PICOS CARACTERISTICOS EXPRESADOS EN GRADOS 2-THETA DE 5,4; 13,3; 15,0; 17,1; 19,5; 21,1; 21,4; 26,9 Y TIENE UN EXPECTRO DE ABSORCION IR QUE TIENE PICOS CARACTERISTICOS EXPRESADOS EN cm-1 DE 3503 cm-1, 2747 cm-1, 2649 cm-1, 1666 cm-1, ENTRE OTROS. SE REFIERE TAMBIEN A U PROCEDIMIENTO DE PREPARACION Y A UNACOMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA DIPEPTIDIL-PEPTIDASA IV (DPP-IV) UTILES EN EL TRATAMIENTO DE DIABETES, INTOLERANCIA A GLUCOSA, OBESIDAD Y SINDROME METABOLICO, ENTRE OTROS
PE2006000304A 2005-03-22 2006-03-20 Nueva sal y polimorfos del inhibidor de la dpp-iv PE20061109A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05102251 2005-03-22

Publications (1)

Publication Number Publication Date
PE20061109A1 true PE20061109A1 (es) 2006-10-13

Family

ID=36406081

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000304A PE20061109A1 (es) 2005-03-22 2006-03-20 Nueva sal y polimorfos del inhibidor de la dpp-iv

Country Status (17)

Country Link
US (1) US7772264B2 (es)
EP (1) EP1888571A2 (es)
JP (1) JP5043825B2 (es)
KR (1) KR20070113305A (es)
CN (1) CN101146801A (es)
AR (1) AR055570A1 (es)
AU (1) AU2006226447B2 (es)
BR (1) BRPI0609580A2 (es)
CA (1) CA2600203C (es)
DO (1) DOP2006000066A (es)
GT (1) GT200600125A (es)
IL (1) IL185768A0 (es)
MX (1) MX2007011546A (es)
PA (1) PA8666701A1 (es)
PE (1) PE20061109A1 (es)
TW (1) TW200700415A (es)
WO (1) WO2006100181A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101791403B1 (ko) 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ-관련 질환의 치료에 사용하기 위한 퓨린 유도체
CZ2008512A3 (cs) 2008-08-26 2010-03-10 Zentiva, A. S Zpusob prípravy vysoce cistého vildagliptinu
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
JP2012517977A (ja) 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2556056A1 (en) 2010-04-06 2013-02-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103787944A (zh) * 2012-11-01 2014-05-14 天津药物研究院 1-(2-氯乙酰基)-2-(s)-腈基吡咯烷的制备方法
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN104262227B (zh) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 一种制备(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的方法
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN106699627A (zh) * 2016-12-29 2017-05-24 青岛黄海制药有限责任公司 一种多相复式非连续生产法制备1‑(2‑氯乙酰基)‑2‑(s)‑氰基吡咯烷的方法
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07247246A (ja) * 1994-03-09 1995-09-26 Daicel Chem Ind Ltd １−フェニル−３−ブチン誘導体とその製造方法
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
PT921125E (pt) * 1997-12-05 2002-06-28 Hoffmann La Roche Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
DE19755436A1 (de) 1997-12-13 1999-06-24 Beiersdorf Ag Verfahren zur zumindest partiellen direkten Beschichtung eines dehnfähigen Trägermaterials mit einer Haftklebemasse
SK161499A3 (en) * 1998-03-30 2000-06-12 Japan Tobacco Inc Process for producing isooxazolidinedione compound
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US6673815B2 (en) * 2001-11-06 2004-01-06 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
EA007613B1 (ru) * 2002-08-29 2006-12-29 Тайсо Фармасьютикал Ко., Лтд. Бензолсульфонатная соль (2s,4s)-1-циано-4-фтор-1-[(2-гидрокси-1,1-диметил)этиламино]ацетилпирролидина
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process

Also Published As

Publication number Publication date
US20060217428A1 (en) 2006-09-28
BRPI0609580A2 (pt) 2010-04-20
US7772264B2 (en) 2010-08-10
JP2008534470A (ja) 2008-08-28
AU2006226447A1 (en) 2006-09-28
TW200700415A (en) 2007-01-01
WO2006100181A2 (en) 2006-09-28
MX2007011546A (es) 2007-10-19
EP1888571A2 (en) 2008-02-20
DOP2006000066A (es) 2006-09-30
CA2600203C (en) 2012-12-04
AR055570A1 (es) 2007-08-22
IL185768A0 (en) 2008-01-06
JP5043825B2 (ja) 2012-10-10
PA8666701A1 (es) 2006-12-07
WO2006100181A3 (en) 2006-11-30
CN101146801A (zh) 2008-03-19
AU2006226447B2 (en) 2009-07-16
GT200600125A (es) 2007-03-16
KR20070113305A (ko) 2007-11-28
CA2600203A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
PE20061109A1 (es) Nueva sal y polimorfos del inhibidor de la dpp-iv
MX2009005863A (es) Procedimiento para la preparacion de compuestos heterociclicos sustituidos por fluorometilo.
MY157365A (en) Chemical compounds and uses
RS51174B (sr) Kombinaciona terapija dijabetesa i stanja povezanih sa njim i za tretman stanja poboljšanih povećanjem nivoa glp-1 u krvi
TW200702330A (en) 3,4,5-Substituted piperidines
TW200712039A (en) Method for producing aromatic compound and aromatic compound
PE20070458A1 (es) Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
PE20110841A1 (es) FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(ß-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO
JP2008501714A5 (es)
EP1756074A4 (en) 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
UA90293C2 (en) Process for preparing lansoprazole
MY148258A (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
UA105778C2 (uk) Піразол-4-n-алкоксикарбоксаміди як мікробіоциди, композиція, що їх містить, та спосіб боротьби із зараженням корисних рослин фітопагенними мікроорганізмами або його попередження з їх використанням
MX339194B (es) Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
MY162640A (en) Thioninium compounds and their use
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
MX2009005139A (es) Formulacion en polvo para inhalacion.
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
PE20090512A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
ATE517644T1 (de) Mikrogelpartikel
HK1106660A2 (en) A modularly constructed container
TW200800960A (en) Novel 2,3-dihydroindole compounds

Legal Events

Date Code Title Description
FC Refusal